期刊文献+

观察益气活血软坚解毒法治疗中晚期原发性肝癌的临床疗效 被引量:1

Clinical efficacy of TCM treatment on advanced primary liver cancer
下载PDF
导出
摘要 目的:观察益气活血软坚解毒法治疗中晚期原发性肝癌的临床疗效。方法:选取来我院进行治疗的中晚期原发性肝癌患者80例,将患者进行随机分组,分为观察组和对照组两组,每组各40例患者。对照组患者采取肝动脉导管介入化疗方案进行治疗,观察组患者采取口服益气活血软坚解毒汤剂进行治疗。结果:观察组患者和对照组患者治疗后癌灶变化(CR+PR)较治疗前变化不显著,组间比较差异不具有统计学意义(P>0.05);观察组患者治疗后的肿瘤稳定率(CR+PR+NC)为70.0%显著高于对照组患者的45.0%,比较差异具有统计学意义(P<0.05)。观察组患者治疗后的神疲乏力、食欲不振、恶心呕吐、疼痛、腹胀等临床症状较对照组显著改善,比较差异具有统计学意义(P<0.05)。观察组治疗后的稳定率为80.0%显著高于对照组患者的50.0%,比较差异具有统计学意义(P<0.05)。结论:益气活血软坚解毒法治疗中晚期原发性肝癌,能够显著提高患者的肿瘤稳定率、显著改善患者的临床症状,显著提高患者的生存质量。 Objective:To observe the clinical efficacy the therapy of Yiqihuoxue Ruanjian Jiedu for advanced primary liver cancer. Methods: 80 patients were randomly divided into observation group and control group, 40 patients in each group. The control group received hepatic artery catheterization chemotherapy treatment, the observation group were taken orally the Yiqihuoxue Ruanjian Jiedu decoction. Results:The changes of foci (CR+PR) after treatment than before treatment did not change significantly, the difference between groups show no statistical significance (P〉0.05); tumor steady rate (CR+PR+NC) of 70.0% was significantly higher than 45.0%, the difference was statistically significant (P〈0.05). Conclusion:Yiqihuoxue Ruanjian Jiedu treatment for advanced primary liver cancer can significantly improve the stability of the cancer and clinical symptoms.
作者 任成刚
机构地区 襄城县中医院
出处 《中医临床研究》 2015年第7期74-75,共2页 Clinical Journal Of Chinese Medicine
关键词 益气活血软坚解毒法治疗 中晚期 原发性肝癌 临床疗效 The Yiqihuoxue Ruanjian Jiedu treatment Advanced Hepatocellular carcinoma Clinical efficacy
  • 相关文献

参考文献4

二级参考文献22

  • 1李兴睿,杨志芳,易继林.肝癌经肝动脉栓塞化疗后VEGF和CD44v6表达的意义[J].世界华人消化杂志,2006,14(13):1305-1308. 被引量:15
  • 2赵增虎,张建宇,刘秀芳,张海,丁瑞亮,李海.TACE对原发性肝癌VEGF和MVD的影响[J].中国误诊学杂志,2007,7(4):717-718. 被引量:12
  • 3应重视大肝癌的综合治疗[J].中国健康月刊,2007(2):42-43. 被引量:2
  • 4程树群.[D].,1998.1-64.
  • 5郝明志,林海澜,陈强,吴晖,余文昌,陈唐庚.沙利度胺联合肝动脉栓塞化疗治疗原发性肝癌随机对照研究[J].癌症,2007,26(8):861-865. 被引量:32
  • 6Kransdorf MJ. Malignant soft-tissue tumors in a large referral population:distribution of diagnoses by age, sex and location[J]. AJR, 1995,164(1) :129-134.
  • 7Yu JS,Kim KW, Kim CS, et al. Primary malignant fibrous histio- cytoma of the liver:imaging features of five surgically confirmed cases[J].Abdom Imaging, 1999,24(4) : 386-391.
  • 8Li YR,Akbari E,Tretiakova MS,et al. Primary hepatic malignant fibrous histiocytoma: clinicopathoiogic characteristics and prog- nostic value of ezrin expression[J].Am J Surg Pathol, 2008,32 (8):1144 1158.
  • 9Alberti-Flor JJ, O'Hara MF, Weaver F, et al. Malignant fibrous histiocytoma of the liver[J].Gastroenterology, 1985,89(4) :890-893.
  • 10Caldeira A, Martin-Carreras F, Pereira E, et al. Malignant fibrous histiocytoma-a rare hepatic tumor [JT. Rev Esp Enferm Dig, 2010,102(2) :146- 147.

共引文献51

同被引文献12

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部